Top Enrolling Physicians for grant year 6/1/2011 – 5/31/2012

<table>
<thead>
<tr>
<th>Physician</th>
<th>Patient Registrations</th>
<th>Treatment Credits</th>
<th>Control Credits</th>
<th>Total Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Carlson</td>
<td>14</td>
<td>2.2</td>
<td>2.5</td>
<td>4.7</td>
</tr>
<tr>
<td>Dr. Bonebrake</td>
<td>7</td>
<td>4</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>Dr. Holden</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Dr. Carlson is our top enroller for June with 13 registrations earning 5.3 credits. However, Dr. Bonebrake is 1.3 credits ahead of Dr. Carlson with credits earned. CRO received notice from NCI on June 28 that our target treatment trials credits for grant year June 1, 2011 through May 31, 2012 is 120 and our target control credits is 60. This is the same target credits set by NCI this past grant year and 10 fewer control credits compared to last year. We are grateful for our investigators and all their efforts in helping us reach our assigned NCI targets.

Newly Formed Cancer Cooperative Group Selects Name

Alliance for Clinical Trials in Oncology (“Alliance”) has been selected as the name for the newly formed cooperative group, which will integrate the scientific and operations functions of the Cancer and Leukemia Group B (CALGB), the North Central Cancer Treatment Group (NCCTG) and the American College of Surgeons Oncology Group (ACOSOG). More than 2,000 members of the three groups selected the name by electronic ballot.

The governing boards of CALGB, NCCTG and ACOSOG have endorsed the proposed Alliance constitution, bylaws and transition plan. The first Alliance Board of Directors Meeting will be held on July 15, 2011, in Chicago. Each group has selected delegates to attend the meeting and establish the governance structure of the new group. The Alliance scientific program leaders, along with scientific leadership from CALGB, NCCTG and ACOSOG, will meet in September, in Chicago, to define the group’s scientific agenda going forward.

NCI Supplements Tornado Victims

CRO has received a $5,137 supplement to assist our research nurse, Rita Glaze, at St. John’s Joplin replenish her office. Rita’s new lap top computer should be arriving shortly. Other office equipment and supplies will be purchased when Rita has a location for them. We are grateful for this supplement and appreciate all of the emails of concern we have received from NCI regarding the May 22 Joplin tornado. They have been most supportive.

Phelps County Regional Hospital a New CRO Affiliate

Phelps County has hired a full time research nurse, Kristi Atkins. Kristi has been a chemo nurse with Drs. Ali & Huq’s office at St. John’s in Rolla. She is scheduled for orientation at Phelps County on August 8th. In mid-August Kristi will be coming to Springfield to start research training with CRO’s Basava Raju. Welcome Kristi! We are most excited to have you on board with us.

CRO’s Annual Report

CRO’s annual report for grant year June 1, 2010 – May 31, 2012 is drafted and awaiting approval of the CRO Executive Board at the board’s next meeting on July 15, 2011. Once given final approval by the board, we will send to all on our CRO Communiqué list.
New Studies Approved in June 2011

Opened at St. John’s only

GOG 0227G A Phase II Evaluation of Brivanib (IND #108417) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix

RTOG 1010 A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

SWOG S0820 A Double Blind Placebo-Controlled Trial of Efornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III

SWOG S0931 EVERST: EVerolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Opened at Cox

GOG 0230D A Phase II Evaluation of Pazopanib (NSC #737754, IND #75648) In the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus

GOG 0235 A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy

GOG 0249 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Cancer

GOG 0256 A Prospective Study of Cognitive Function During Chemotherapy for the Front Line Treatment of Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

GOG 0263 Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy

RTOG 1010 A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

Studies Closed in June

SWOG S0230 Phase II Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer

NCCTG N07C2 The Use of Wisconsin Ginseng (panax quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study (Partial closure – open to minority patients only)